Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Liver Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Liver Fibrosis - Pipeline Review, H2 2016', provides an overview of the Liver Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis - The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects - The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Liver Fibrosis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Liver Fibrosis Overview 9 Therapeutics Development 10 Pipeline Products for Liver Fibrosis - Overview 10 Pipeline Products for Liver Fibrosis - Comparative Analysis 11 Liver Fibrosis - Therapeutics under Development by Companies 12 Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes 15 Liver Fibrosis - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Liver Fibrosis - Products under Development by Companies 18 Liver Fibrosis - Products under Investigation by Universities/Institutes 22 Liver Fibrosis - Companies Involved in Therapeutics Development 23 Advinus Therapeutics Ltd 23 Akarna Therapeutics Ltd. 24 Angion Biomedica Corp. 25 Asubio Pharma Co., Ltd. 26 aTyr Pharma, Inc. 27 Beijing Kawin Technology Share-Holding Co., Ltd. 28 BioLineRx, Ltd. 29 Bioneer Corporation 30 BiOrion Technologies B.V. 31 Bird Rock Bio, Inc. 32 Bristol-Myers Squibb Company 33 Cellmid Limited 34 ContraVir Pharmaceuticals, Inc. 35 Dicerna Pharmaceuticals, Inc. 36 Digna Biotech, S.L. 37 Dr. Falk Pharma GmbH 38 Dynavax Technologies Corporation 39 Evotec AG 40 Galectin Therapeutics, Inc. 41 Genfit SA 42 Gilead Sciences, Inc. 43 GNI Group Ltd. 44 HEC Pharm Co., Ltd. 45 Immuron Limited 46 Intercept Pharmaceuticals, Inc. 47 INVENT Pharmaceuticals, Inc. 48 Isarna Therapeutics GmbH 49 KineMed, Inc. 50 LG Life Science LTD. 51 Nitto Denko Corporation 52 Pfizer Inc. 53 Pharmaxis Limited 54 Promedior, Inc. 55 Promethera Biosciences S.A. 56 ProMetic Life Sciences Inc. 57 Ribomic Inc. 58 RXi Pharmaceuticals Corporation 59 Silence Therapeutics Plc 60 TCM Biotech International Corp 61 Vascular Biogenics Ltd. 62 Virobay Inc. 63 XTuit Pharmaceuticals, Inc. 64 Liver Fibrosis - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Combination Products 66 Assessment by Target 67 Assessment by Mechanism of Action 71 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 ANG-3070 - Drug Profile 78 ANG-3281 - Drug Profile 79 Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile 80 Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 81 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 82 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 83 Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile 84 Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile 85 Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile 86 ASB-14780 - Drug Profile 87 BL-1210 - Drug Profile 88 BMS-986171 - Drug Profile 89 BOT-162 - Drug Profile 90 BOT-191 - Drug Profile 91 CAB-102 - Drug Profile 92 CPI-43132 - Drug Profile 94 CT-140 - Drug Profile 97 DB-036 - Drug Profile 98 Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile 99 Drugs for Tissue Fibrosis - Drug Profile 100 DV-1079 - Drug Profile 101 F-351 - Drug Profile 103 Gene Therapy for Liver Fibrosis - Drug Profile 105 GMCT-01 - Drug Profile 106 GRMD-02 - Drug Profile 110 GS-444217 - Drug Profile 121 HEC-585 - Drug Profile 122 HepaStem - Drug Profile 123 IMM-124E - Drug Profile 125 INT-767 - Drug Profile 128 INV-240 - Drug Profile 129 ISTH-0047 - Drug Profile 130 KW-0 - Drug Profile 132 KW-012 - Drug Profile 133 LC-280126 - Drug Profile 134 melittin - Drug Profile 135 Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile 136 MOR-8457 - Drug Profile 137 MRI-1867 - Drug Profile 138 ND-L02s0201 - Drug Profile 139 norursodeoxycholic acid - Drug Profile 141 noscapine - Drug Profile 142 PBI-4050 - Drug Profile 143 PRM-151 - Drug Profile 148 Proteins for Liver Fibrosis - Drug Profile 153 PXS-4820 - Drug Profile 154 PXS-5033A - Drug Profile 155 RBM-006 - Drug Profile 156 Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile 157 RXI-209 - Drug Profile 158 RYI-018 - Drug Profile 159 selonsertib - Drug Profile 160 selonsertib + simtuzumab - Drug Profile 161 Small Molecule for Liver Fibrosis - Drug Profile 162 Small Molecule for Liver Fibrosis - Drug Profile 163 Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile 164 Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile 165 Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile 166 Small Molecules for Hepatic Fibrosis - Drug Profile 167 Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile 168 Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile 169 Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile 170 TCM-808FB - Drug Profile 171 TGFTX-4 - Drug Profile 172 VB-201 - Drug Profile 173 VB-703 - Drug Profile 176 VBY-376 - Drug Profile 177 VBY-825 - Drug Profile 178 Liver Fibrosis - Dormant Projects 179 Liver Fibrosis - Discontinued Products 183 Liver Fibrosis - Product Development Milestones 184 Featured News & Press Releases 184 Appendix 193 Methodology 193 Coverage 193 Secondary Research 193 Primary Research 193 Expert Panel Validation 193 Contact Us 193 Disclaimer 194
List of Tables
Number of Products under Development for Liver Fibrosis, H2 2016 15 Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Development by Companies, H2 2016 (Contd..3) 26 Products under Investigation by Universities/Institutes, H2 2016 27 Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016 28 Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016 29 Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016 30 Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016 31 Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016 32 Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016 33 Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016 34 Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016 35 Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016 36 Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016 37 Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016 38 Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016 39 Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 40 Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016 41 Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016 42 Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016 43 Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016 44 Liver Fibrosis - Pipeline by Evotec AG, H2 2016 45 Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016 46 Liver Fibrosis - Pipeline by Genfit SA, H2 2016 47 Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016 48 Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016 49 Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016 50 Liver Fibrosis - Pipeline by Immuron Limited, H2 2016 51 Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 52 Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 53 Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016 54 Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016 55 Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016 56 Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016 57 Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016 58 Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016 59 Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016 60 Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016 61 Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016 62 Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016 63 Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016 64 Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016 65 Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016 66 Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016 67 Liver Fibrosis - Pipeline by Virobay Inc., H2 2016 68 Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016 69 Assessment by Monotherapy Products, H2 2016 70 Assessment by Combination Products, H2 2016 71 Number of Products by Stage and Target, H2 2016 73 Number of Products by Stage and Mechanism of Action, H2 2016 77 Number of Products by Stage and Route of Administration, H2 2016 80 Number of Products by Stage and Molecule Type, H2 2016 82 Liver Fibrosis - Dormant Projects, H2 2016 184 Liver Fibrosis - Dormant Projects (Contd..1), H2 2016 185 Liver Fibrosis - Dormant Projects (Contd..2), H2 2016 186 Liver Fibrosis - Dormant Projects (Contd..3), H2 2016 187 Liver Fibrosis - Discontinued Products, H2 2016 188
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
